Live Breaking News & Updates on Stellanova Therapeutics

Stay updated with breaking news from Stellanova therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatableHOUSTON, June 03, 2021 (GLOBE NEWSWIRE) Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by Sporos Bioventures, LLC. The funds will advance ....

Tumor Microenvironment , Stellanova Therapeutics , Sporos Bioventures , Triple Negative Breast Cancer , Pancreatic Cancer , Monoclonal Antibody , Biotechnology Company ,

Stellanova Therapeutics Closes $15.5M Series A Financing Round


Stellanova Therapeutics Closes $15.5M Series A Financing Round
The round was led by Sporos Bioventures.
The company intends to use the funds to advance its lead antibody asset to first-in-human clinical trials for oncology, establish its discovery platform, and build its team.
Led by Rosa Hwang, M.D., co-founder, Stellanova is focused on targeting the many pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment. CAFs play essential roles in promoting cancer growth and metastasis, spurring angiogenesis, suppressing anti-tumor immunity, and fostering chemoresistance. The company’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance. In pre-clinical studies, treatment with anti-DKK3 monoclonal antibody and immune checkpoint inhibitor therapy has produced sustain ....

United States , Rosa Hwang , Sporos Bioventures , Emmanuelle Schuler , Houston Texas Medical Center , Stellanova Therapeutics Inc , Stellanova Therapeutics , Chief Executive , Corallis Consulting , Texas Medical , ஒன்றுபட்டது மாநிலங்களில் , ரோசா ஹ்வ்யாஂக் , இம்மானுவேல் ஸ்கூலர் , ஹூஸ்டன் டெக்சாஸ் மருத்துவ மையம் , தலைமை நிர்வாகி , டெக்சாஸ் மருத்துவ ,